Mail-order pharmacy use incentives would be banned by Rep. Lowey bill backed by NARD, NACDS.
HEALTH PLAN INCENTIVES FOR USE OF MAIL-ORDER PHARMACY would be eliminated by the "Prescription Drug Benefit Equity Act" (HR 3991) introduced by Rep. Lowey (D-N.Y.) Aug. 2. The bill, which was referred to the Committees on Commerce, Ways & Means and Economic & Educational Opportunities, is not expected to move during the current session.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth